OBJECTIVE: Few studies have investigated whether the utility of social support for patients with a relapsing, remitting illness varies by activity level of the disease. Our goal was to determine whether disease status (relapse vs remission) moderates the effect of medication-related support from physicians and partners on the health-related quality of life (HRQOL) of patients with vasculitis. METHODS: Patients with vasculitis (n = 228) completed baseline measures of disease status and medication-related support and a 3-month followup measure of HRQOL (RAND 36-item health survey 1.0). We calculated 8 HRQOL dimensions: physical functioning, physical role limitations, bodily pain, general health, vitality, social functioning, emotional role limitations, and mental health. Bonferroni-corrected t tests compared the HRQOL of patients in relapse to patients in remission, and multivariate analysis of covariance determined whether disease status moderated the effect of medication-related support from physicians and partners on patient HRQOL. Wilks' lambda assessed whether the support-by-disease status interaction terms were significant. RESULTS: Relapsing patients reported significantly worse quality of life compared with nonrelapsing patients for every HRQOL dimension except physical role limitations. Disease status did not moderate the effect of physician (lambda = 0.48; p = 0.86) or partner (lambda = 1.51; p = 0.16) medication-related support on HRQOL, although greater physician and partner support predicted better HRQOL for all dimensions except bodily pain and vitality. CONCLUSION: Vasculitis patients experience compromised HRQOL but the magnitude of the compromise is greater for patients experiencing a relapse. Medication-related support from physicians and partners is beneficial for patients' HRQOL regardless of disease status.
OBJECTIVE: Few studies have investigated whether the utility of social support for patients with a relapsing, remitting illness varies by activity level of the disease. Our goal was to determine whether disease status (relapse vs remission) moderates the effect of medication-related support from physicians and partners on the health-related quality of life (HRQOL) of patients with vasculitis. METHODS:Patients with vasculitis (n = 228) completed baseline measures of disease status and medication-related support and a 3-month followup measure of HRQOL (RAND 36-item health survey 1.0). We calculated 8 HRQOL dimensions: physical functioning, physical role limitations, bodily pain, general health, vitality, social functioning, emotional role limitations, and mental health. Bonferroni-corrected t tests compared the HRQOL of patients in relapse to patients in remission, and multivariate analysis of covariance determined whether disease status moderated the effect of medication-related support from physicians and partners on patient HRQOL. Wilks' lambda assessed whether the support-by-disease status interaction terms were significant. RESULTS: Relapsing patients reported significantly worse quality of life compared with nonrelapsing patients for every HRQOL dimension except physical role limitations. Disease status did not moderate the effect of physician (lambda = 0.48; p = 0.86) or partner (lambda = 1.51; p = 0.16) medication-related support on HRQOL, although greater physician and partner support predicted better HRQOL for all dimensions except bodily pain and vitality. CONCLUSION:Vasculitispatients experience compromised HRQOL but the magnitude of the compromise is greater for patients experiencing a relapse. Medication-related support from physicians and partners is beneficial for patients' HRQOL regardless of disease status.
Authors: Maarten M Boomsma; Marc Bijl; Coen A Stegeman; Cees G M Kallenberg; Gary S Hoffman; Jan Willem Cohen Tervaert Journal: Arthritis Rheum Date: 2002-04-15
Authors: David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey Journal: N Engl J Med Date: 2003-07-03 Impact factor: 91.245
Authors: Eva Reinhold-Keller; Karen Herlyn; Rosemarie Wagner-Bastmeyer; Joachim Gutfleisch; Hartmut H Peter; Heiner H Raspe; Wolfgang L Gross Journal: Arthritis Rheum Date: 2002-06-15
Authors: Delesha M Carpenter; Amy E Meador; Emily A Elstad; Susan L Hogan; Robert F DeVellis Journal: Clin Exp Rheumatol Date: 2012-05-10 Impact factor: 4.473
Authors: Delesha M Carpenter; Carolyn T Thorpe; Dayna S Alexander; Adam J Sage; Megan Lewis; Susan L Hogan; Lorie L Geryk; Robert F DeVellis Journal: Curr Rheumatol Rev Date: 2016
Authors: Dayna S Alexander; Susan L Hogan; Joanne M Jordan; Robert F DeVellis; Delesha M Carpenter Journal: Patient Prefer Adherence Date: 2017-01-12 Impact factor: 2.711